NovoCure Limited
NVCR
$17.96
$0.070.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.27% | 18.82% | 14.63% | 8.33% | 0.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.27% | 18.82% | 14.63% | 8.33% | 0.61% |
| Cost of Revenue | 7.18% | 6.82% | 9.29% | 8.70% | 13.32% |
| Gross Profit | 21.98% | 22.84% | 16.38% | 8.22% | -3.02% |
| SG&A Expenses | 11.88% | 10.84% | 1.01% | 8.39% | 17.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.44% | 5.34% | 0.34% | 4.41% | 9.28% |
| Operating Income | 20.01% | 25.02% | 31.90% | 6.06% | -39.82% |
| Income Before Tax | 24.66% | 31.59% | 38.37% | 12.32% | -32.12% |
| Income Tax Expenses | 68.16% | 144.82% | 206.82% | 105.78% | 93.98% |
| Earnings from Continuing Operations | 14.82% | 18.55% | 24.07% | 3.25% | -36.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.82% | 18.55% | 24.07% | 3.25% | -36.75% |
| EBIT | 20.01% | 25.02% | 31.90% | 6.06% | -39.82% |
| EBITDA | 21.30% | 26.22% | 33.23% | 6.49% | -42.52% |
| EPS Basic | 16.28% | 19.77% | 25.11% | 4.62% | -34.68% |
| Normalized Basic EPS | 19.57% | 26.17% | 29.67% | 3.26% | -40.49% |
| EPS Diluted | 16.27% | 19.76% | 25.11% | 4.61% | -34.63% |
| Normalized Diluted EPS | 19.57% | 26.17% | 29.67% | 3.26% | -40.49% |
| Average Basic Shares Outstanding | 1.73% | 1.40% | 1.52% | 1.62% | 1.69% |
| Average Diluted Shares Outstanding | 1.73% | 1.40% | 1.52% | 1.62% | 1.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |